Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Anti-Infective Risk Reduction: GeneSoft Skips to the Clinic

This article was originally published in Start Up

Executive Summary

GeneSoft Inc., a company founded to commercialize technology for interfering with gene expression using compounds that bind to grooves on DNA sequences has a wide scope of potential applications before it, but it has chosen to position itself as an anti-infective specialty pharmaceuticals company. Its direction stems not merely from unpopularity of platform models, but because it believes it's learned the lessons of its in-licensing anti-infective forebears and can pursue the strategy with lower risk.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts